Lead is a neurotoxicant that accumulates in bone with a half life of 25-30 years. To evaluate the association of lead biomarkers and cognitive function, a cohort of exposed and nonexposed workers who had been previously assessed in 1982 was retested approximately 22 years later. For the current assessment, both blood lead and tibia bone lead levels were determined. In addition, cognitive function was tested with the Pittsburgh Occupational Exposures Test battery, which had previously been administered in 1982. In exposed workers, bone lead level predicted lower current cognitive performance and cognitive decline over 22 years. In those lead-exposed workers older than age 55, higher levels of bone lead predicted poorer cognitive scores, suggesting vulnerability for older workers with higher past lead exposure. Finally, there was no association with bone lead level and recency of exposure, suggesting that cumulative body burden is most likely responsible for the progressive cognitive decrement evidenced with vulnerability because of aging.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1037/a0013757 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identifying Patients at Risk for a Facility Discharge Following Elective Total Joint Arthroplasty Using Preoperative Clinical Findings and Patient-Reported Outcome Scores.
J Arthroplasty
January 2025
Hartford Healthcare Bone and Joint Institute, 32 Seymour Street, Hartford, CT 06106; Orthopaedic Associates of Hartford, 31 Seymour Street, Hartford, CT 06106.
Introduction: Facility discharges following an elective, primary, total joint arthroplasty are infrequent, but are associated with poor outcomes and significant cost. Therefore, investigating ways to identify patients most likely to be discharged to a facility could improve patient care, reduce costs, and potentially lead to strategies to mitigate these risks.
Methods: A total of 3,198 patients who underwent a total hip or knee arthroplasty between June 2021 and June 2023 were included in this study.
[Transcutaneous osseointegrated prostheses systems (TOPS) for rehabilitation following limb loss : Surgical approach for necessary removal of the implant].
Oper Orthop Traumatol
January 2025
Klinik für Unfall‑, Hand- und Wiederherstellungschirurgie, Universitätsmedizin Rostock, Schillingallee 35, 18057, Rostock, Deutschland.
Objective: Removal of a transcutaneous osseintegrated endo-fix stem (ESKA Orthopaedic, Lübeck, Germany) following a fatigue fracture of the implant, whilst protecting the residual femur bone to allow transcutaneous osseointegrated prosthesis system (TOPS) reimplantation.
Indications: A patient's request for a further TOPS implantation following a fatigue fracture of a circular osseointegrated implant stem.
Contraindications: Impending destruction of the bone tube through mobilisation of the femoral implant stem with insufficient thickness of the cortical wall (< 2-3 mm).
Beta-tricalcium phosphate patient-specific gap implants in bilateral sagittal split osteotomy: an innovative treatment method to enhance the mandibular border contour. Part 1: concept and workflow.
Int J Oral Maxillofac Surg
January 2025
Division of Maxillofacial Surgery, Department of Surgery, AZ Sint-Jan Brugge AV, Bruges, Belgium; Oral and Maxillofacial Surgery Unit, Division of Surgery, Barzilai Medical Center, Affiliated to Ben-Gurion University of the Negev, Ashkelon, Israel.
Antegonial notching can occur after bilateral sagittal split osteotomy (BSSO) and may lead to unpleasant aesthetic outcomes in both young and older patients. This clinical study presents a new concept to potentially overcome this problem and describes the workflow. Beta-tricalcium phosphate patient-specific gap implants (β-TCP gap-PSIs) are biocompatible and resorbable bone grafts that are placed in the space of the osteotomy gap during orthognathic procedures; they are virtually planned and printed in 3D.
View Article and Find Full Text PDFANKRD11 binding to cohesin suggests a connection between KBG syndrome and Cornelia de Lange syndrome.
Proc Natl Acad Sci U S A
January 2025
Shenzhen Key Laboratory of Biomolecular Assembling and Regulation, Department of Neuroscience, School of Life Sciences, Southern University of Science and Technology, Shenzhen 518055, China.
Ankyrin Repeat Domain-containing Protein 11 () is a causative gene for KBG syndrome, a significant risk factor for Cornelia de Lange syndrome (CdLS), and a highly confident autism spectrum disorder gene. Mutations of lead to developmental abnormalities in multiple organs/tissues including the brain, craniofacial and skeletal bones, and tooth structures with unknown mechanism(s). Here, we find that ANKRD11, via a short peptide fragment in its N-terminal region, binds to the cohesin complex with a high affinity, implicating why mutation can cause CdLS.
View Article and Find Full Text PDFEarly and multiple doses of zoledronate mitigates rebound bone loss following withdrawal of RANKL inhibition.
J Bone Miner Res
January 2025
Cancer Ecosystems Program, Garvan Institute of Medical Research, Sydney, NSW, Australia.
Rebound bone loss following denosumab discontinuation is an important barrier in the effective long-term treatment of skeletal disorders. This is driven by increased osteoclastic bone resorption following the offset of RANKL inhibition, and sequential osteoclast-directed therapy has been utilised to mitigate this. However, current sequential treatment strategies intervene following the offset of RANKL inhibition and this approach fails to consistently prevent bone loss.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!